Consensus Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse Other stock markets 04:00:02 2024-05-16 pm EDT			5-day change	1st Jan Change
9.77 ^USD	+0.41%		+9.78%	+92.32%

May. 15	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial	CI
May. 14	Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target	MT

Evolution of the average Target Price on Actinium Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7dffa3bee.CBwcHt6xgAD8nSUMEHGN6IL9VUoLRhSFLv8S7tKSS40.YndKf53Q5EuXpGtjIx7aqd2nJyhPJ1jrSp59iZ3lHPt9QyhUkeXRSsjlTg~27e008f651cf50be9156dfc29bcaa208

Analyst Recommendations on Actinium Pharmaceuticals, Inc.

Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target	May. 14	MT
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating	Mar. 19	MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating	Dec. 11	MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60	23-09-06	MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating	23-08-15	MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating	23-03-02	MT
William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform	23-02-21	MT
HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating	22-10-31	MT
B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating	22-10-31	MT
Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target	22-09-08	MT
B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated	22-08-25	MT
Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating	22-04-13	MT
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML	21-12-14	CI
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating	21-08-03	MT
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating	21-04-01	MT
Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH	20-12-08	CI
ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target	20-11-05	MT
Actinium Pharmaceuticals : Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10%	20-11-04	MT
Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML	20-11-04	CI
Actinium Pharmaceuticals, Inc. Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting	19-12-09	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.85 USD

Average target price

25.4 USD

Spread / Average Target

+157.87%

High Price Target

50 USD

Spread / Highest target

+407.61%

Low Price Target

9.8 USD

Spread / Lowest Target

-0.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Actinium Pharmaceuticals, Inc.

Stephens Inc.
Maxim
B. Riley
HSBC
HC Wainwright
William Blair & Co.
Cantor Fitzgerald
Alliance Global Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar